This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwakawa, R. Articles by Yokota, J. Search for Related Content PubMed PubMed Citation Articles by Iwakawa, R. Articles by Yokota, J.

Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma

Authors' Affiliations: ¹ Biology Division, National Cancer Center Research Institute, ² Thoracic Surgery Division and ³ Diagnostic Pathology Division, National Cancer Center Hospital, Tokyo, Japan; ⁴ Department of Pathology, Institute of Basic Medical Sciences, Graduate School of Comprehensive Human Sciences, Tsukuba University, Ibaraki, Japan; ⁵ Department of Neuro-Oncology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan; and ⁶ Department of Biological Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science, Chiba, Japan

Requests for reprints: Jun Yokota, Biology Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-33547-5272; Fax: 81-33542-0807; E-mail: jyokota{at}ncc.go.jp.

Purpose: The p16 gene is frequently inactivated in lung adenocarcinoma. In particular, homozygous deletions (HD) have been frequently detected in cell lines; however, their frequency and specificity is not well-established in primary tumors. The purpose of this study was to elucidate the prevalence and the timing for the occurrence of p16 HDs in lung adenocarcinoma progression in vivo.

Experimental Design: Multiple ligation-dependent probe amplification was used for the detection of p16 HDs in 28 primary small-sized lung adenocarcinomas and 22 metastatic lung adenocarcinomas to the brain. Cancer cells were isolated from primary adenocarcinoma specimens by laser capture microdissection. HDs were confirmed by quantitative real-time genomic PCR analysis.

Results: HDs were detected in 8 of 28 (29%) primary tumors, including 2 of 8 (25%) noninvasive bronchioloalveolar carcinomas, and 5 of 22 (26%) brain metastases, respectively. No significant associations were observed between p16 HDs and gender, age, smoking history, stage, and prognosis. HDs were detected with similar frequencies (17–29%) among adenocarcinomas with epidermal growth factor receptor (EGFR) mutations, with KRAS mutations, and without EGFR/KRAS mutations, and with similar frequencies (22–28%) between adenocarcinomas with and without p53 mutations.

Conclusions: p16 HDs occur early in the development of lung adenocarcinomas and with similar frequencies among EGFR type, KRAS type, and non-EGFR/KRAS type lung adenocarcinomas. Tobacco carcinogens would not be a major factor inducing p16 HDs in lung adenocarcinoma progression.

This article has been cited by other articles:

				H. Nakanishi, S. Matsumoto, R. Iwakawa, T. Kohno, K. Suzuki, K. Tsuta, Y. Matsuno, M. Noguchi, E. Shimizu, and J. Yokota Whole Genome Comparison of Allelic Imbalance between Noninvasive and Invasive Small-Sized Lung Adenocarcinomas Cancer Res., February 15, 2009; 69(4): 1615 - 1623. [Abstract] [Full Text] [PDF]